Climb Bio Stock Today

CLYM Stock   1.95  0.08  3.94%   

Performance

0 of 100

 
Weak
 
Strong
Very Weak

Odds Of Distress

Over 82

 
High
 
Low
Very High
Climb Bio is selling at 1.95 as of the 20th of December 2024; that is 3.94 percent decrease since the beginning of the trading day. The stock's lowest day price was 1.95. Climb Bio has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Climb Bio symbol was changed from ELYM on 3rd of October 2024. The performance scores are derived for the period starting the 20th of November 2024 and ending today, the 20th of December 2024. Click here to learn more.
IPO Date
10th of August 2021
Category
Healthcare
Climb Bio is entity of United States. It is traded as Stock on NASDAQ exchange. More on Climb Bio

Moving together with Climb Stock

  0.74DWTX Dogwood Therapeutics, Symbol ChangePairCorr
  0.74EFTR Effector TherapeuticsPairCorr
  0.73EMMA Emmaus Life SciencesPairCorr

Moving against Climb Stock

  0.65GRCE Grace Therapeutics, Symbol ChangePairCorr
  0.62EPRX Eupraxia PharmaceuticalsPairCorr
  0.57FRTX Fresh Tracks TherapeuticsPairCorr
  0.56VAXX VaxxinityPairCorr
  0.44FBIOP Fortress Biotech PrefPairCorr
  0.38EVLO Evelo BiosciencesPairCorr

Climb Stock Highlights

Older SymbolELYM
President CEOBAO BCh
Business ConcentrationPharmaceutical Products, Biotechnology, Healthcare, NASDAQ Composite, NASDAQ Health Care, Biotechnology, Healthcare (View all Sectors)
Average Analyst Recommendation
Climb Bio (CLYM) is traded on NASDAQ Exchange in USA. It is located in PMB #117, 2801 Centerville Road, Wilmington, DE, United States, 19808-1609 and employs 9 people. Climb Bio was previously known as Eliem Therapeutics and was traded on NASDAQ Exchange under the symbol ELYM. Climb Bio is listed under Pharmaceutical Products category by Fama And French industry classification. The company conducts business under Healthcare sector and is part of Biotechnology industry.
Check Climb Bio Probability Of Bankruptcy

Climb Bio Historical Income Statement

At this time, Climb Bio's Research Development is very stable compared to the past year. As of the 20th of December 2024, Total Other Income Expense Net is likely to grow to about 562.8 K, while Selling General Administrative is likely to drop about 16.1 M. View More Fundamentals

Climb Stock Against Markets

Climb Bio Corporate Executives

Elected by the shareholders, the Climb Bio's board of directors comprises two types of representatives: Climb Bio inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Climb. The board's role is to monitor Climb Bio's management team and ensure that shareholders' interests are well served. Climb Bio's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Climb Bio's outside directors are responsible for providing unbiased perspectives on the board's policies.
MD MBACOO OfficerProfile
When determining whether Climb Bio is a strong investment it is important to analyze Climb Bio's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Climb Bio's future performance. For an informed investment choice regarding Climb Stock, refer to the following important reports:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Climb Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.
To learn how to invest in Climb Stock, please use our How to Invest in Climb Bio guide.
You can also try the Stocks Directory module to find actively traded stocks across global markets.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Climb Bio. If investors know Climb will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Climb Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Climb Bio is measured differently than its book value, which is the value of Climb that is recorded on the company's balance sheet. Investors also form their own opinion of Climb Bio's value that differs from its market value or its book value, called intrinsic value, which is Climb Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Climb Bio's market value can be influenced by many factors that don't directly affect Climb Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Climb Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Climb Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Climb Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.